https://medicine.ouhsc.edu/directory Parent Page: Directory id: 22535 Active Page: Detailsid:23325

Directory

Categories

Kevin Brown, PhD
Microbiology & Immunology

Kevin Brown, PhD

Assistant Professor


Lab: BMSB 913
Office: BMSB 907

405-271-2133 ext:46630

kevin-brown@ouhsc.edu


Academic Section(s):

Microbiology and Immunology


Education:

Ph.D. University of Oklahoma Health Sciences Center
B.S. Oklahoma Christian University


Fellowship:

Washington University in St. Louis


Clinical/Research Interests:

Cellular and molecular biology of apicomplexan parasites. Areas of special interest include parasite motility, protein secretion, second messenger signaling, genetics, and pathogenesis.

Apicomplexan parasites remain a leading threat to global health due to their ability to invade, co-opt, and destroy host cells. Apicomplexans use gliding motility to enter and exit host cells but must remain static for intracellular replication, stage development, and chronic persistence. To precisely regulate motility, apicomplexans utilize cyclic nucleotide signaling where cGMP and cAMP cascades stimulate and suppress motility, respectively. The primary focus of our laboratory is to identify and characterize enzymes responsible for cyclic nucleotide signaling in apicomplexan parasites. Our workhorse parasite of choice is Toxoplasma gondii, a highly tractable apicomplexan that infects billions of humans and countless animals worldwide. Current projects relate to three key signaling questions:

  1. How do apicomplexans generate cyclic nucleotides in response to their host environment?
  2. How do apicomplexans buffer and integrate opposing cGMP and cAMP signals into a unified motile response?
  3. What targets of cyclic nucleotide-dependent kinases are required for activation or suppression of apicomplexan motility?

Our research pipeline utilizes bioinformatics, transcriptomics and proteomics to identify candidate signaling enzymes that are conserved among all apicomplexans. Next, candidate enzymes are screened for function in vitro and in vivo using reverse genetics. Finally, key molecular determinants of enzyme activity are defined using genetic and biochemical mutational analyses. Our long-term goal is to leverage these protein/function studies to rationally develop novel anti-apicomplexan drug and/or vaccine therapies.


Select Publications:

  • Moss WJ, Patterson CE, Jochmans AK, Brown KM. (2022) Functional Analysis of the Expanded Phosphodiesterase Gene Family in Toxoplasma gondii Tachyzoites. mSphere. 7(1):e00793-21. https://doi.org/10.1128/msphere.00793-21.
  • Brown, K.M. and Sibley, L.D. (2018) Essential cGMP Signaling in Toxoplasma is Initiated by a Hybrid P-Type ATPase-Guanylate Cyclase. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2018.10.015.
  • Long, S., Brown, K.M., Drewry, L.L., Anthony, B., Phan, I.Q.H., Sibley, L.D. (2017) Calmodulin-like proteins localized to the conoid regulate motility and cell invasion by Toxoplasma gondiiPLoS Pathog. 13(5): e1006379.
  • Brown, K.M., Long, S., Sibley, L.D. (2017) Plasma membrane association by N-acylation governs PKG function in Toxoplasma gondiimBio 8:e00375-17. https://doi.org/10.1128/mBio.00375-17.
  • Brown, K.M., Lourido, S., Sibley, L.D. (2016) Serum Albumin Stimulates Protein Kinase G-dependent Microneme Secretion in Toxoplasma gondiiJ Biol Chem. 2016;291(18):9554–65.
  • Shen, B., Brown, K.M., Lee, T.D., Sibley, L.D. (2014) Efficient gene disruption in diverse strains of Toxoplasma gondii using CRISPR/CAS9. mBio. 5(3):e01114-14. doi:10.1128/mBio.01114-14.

Related Resource Publications:

  • Moss WJ, Brusini L, Kuehnel R, Brochet M, Brown KM. (2024) Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential. mBio15:e03056-23. https://doi.org/10.1128/mbio.03056-23
  • Long, S., Brown, K.M. and Sibley, L.D. (2018) CRISPR-mediated Tagging with BirA Allows Proximity Labeling in Toxoplasma gondiiBio-protocol 8(6): e2768. DOI: 10.21769/BioProtoc.2768.
  • Brown, K.M., Long, S. and Sibley, L.D. (2018) Conditional Knockdown of Proteins Using Auxin-inducible Degron (AID) Fusions in Toxoplasma gondiiBio-protocol 8(4): e2728. DOI: 10.21769/BioProtoc.2728.
  • Shen, B., Brown, K., Long, S. and Sibley L.D. (2017) Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondiiMeth Mol Biol. 2017;1498:79–103.

A complete list of Kevin Brown's publications can be found here.